Scripta Insights Joins Eli Lilly TuneLab to Advance Neurodegenerative Drug Discovery

According to a recent LinkedIn post from Scripta Insights, the company is participating in Eli Lilly and Company’s TuneLab program, which focuses on applying artificial intelligence and machine learning to drug discovery. The post indicates that Scripta expects to use Lilly’s predictive ADME and chemical profiling tools while contributing its own data to the Rhino Federated Computing platform.

The company’s LinkedIn post highlights that these capabilities are intended to support Scripta’s biology‑first approach to modulating transcription factor activity for neurodegenerative disease drug discovery. For investors, involvement in TuneLab may suggest access to advanced R&D infrastructure, potential acceleration of pipeline decisions, and closer alignment with a major pharmaceutical player, though the post does not reference specific financial terms or timelines.

As described in the post, the collaboration appears focused on improving rational decision‑making around Scripta’s novel chemistry and enhancing TuneLab’s continuous model improvement with additional datasets. If successful, such integration of external AI platforms with Scripta’s internal research could strengthen its competitive position in neurodegenerative therapeutics and signal increasing reliance on data‑driven approaches within the sector.